반응식
[CH:1]1([C:4]2[CH:5]=[CH:6][C:7]([C:17]([OH:19])=O)=[N:8][C:9]=2[S:10]([CH2:13][CH:14]([CH3:16])[CH3:15])(=[O:12])=[O:11])[CH2:3][CH2:2]1.Cl.[F:21][C:22]([F:32])([F:31])[C@H:23]([C:25]1[CH:26]=[N:27][CH:28]=[CH:29][CH:30]=1)[NH2:24]>>[F:32][C:22]([F:21])([F:31])[C@@H:23]([NH:24][C:17]([C:7]1[CH:6]=[CH:5][C:4]([CH:1]2[CH2:2][CH2:3]2)=[C:9]([S:10]([CH2:13][CH:14]([CH3:15])[CH3:16])(=[O:11])=[O:12])[N:8]=1)=[O:19])[C:25]1[CH:26]=[N:27][CH:28]=[CH:29][CH:30]=1참가 물질
3
실험 절차
The title compound was synthesized in analogy to Example 1, using 5-cyclopropyl-6-(isobutylsulfonyl)picolinic acid (Example 351 b) and (S)-2,2,2-trifluoro-1-(pyridin-3-yl)ethanamine hydrochloride (CAN 336105-46-5) as starting materials. MS (EI): m/e=442.4 [M+H]+.
출처 및 근거
- ORD 기록
- ord-d5a9286e68084d88b1121a74b15d230b
- 출처 데이터셋
- uspto-grants-2016_04
- 특허 번호
- US09321727B2
연결된 노트
불러오는 중…